

Page 15, please rewrite the paragraph as follows:

Table: Peptides from four *Plasmodium falciparum* antigens, circumsporozoite protein (cp), thrombospondin-related anonymous protein (tr) spirozoite hepatocyte binding antigen (sh) and liver-stage antigen-1 (ls), that are here identified as CTL epitopes or as potential CTL epitopes for particular HLA class I molecules. Epitopes are shown in bold type. The position of the first amino acid of the peptide in the published amino acid sequence (CSP - Dame *et al.*, 1984; LSA-1 - Zhu *et al.*, 1991; TRAP - Robson *et al.*, 1988) is shown. Note that tr57 is 11 amino acids in length. The standard one letter amino acid code is used.

IN THE CLAIMS

Cancel without prejudice claims 1-11.

Kindly add the following new claims:

12. (New) An isolated peptide consisting of between 9 and 100 contiguous amino acids of the thrombospondin related anonymous protein (TRAP) malarial antigen, including the amino acid sequence of at least one of SEQ ID Nos. 1 or 17, said amino acid sequence of SEQ ID No. 1 being capable of binding to human leukocyte antigen HLA-A2 when said sequence is present in said isolated peptide, said amino acid sequence of SEQ ID No. 17 being capable of binding to human leukocyte antigen HLA-B8 when said sequence is present in said isolated peptide, and said sequences being recognized by cytotoxic T lymphocytes (CTLs) from individuals currently or previously infected by Plasmodium when one or both sequences are present in said isolated peptide.

13. (New) The isolated peptide according to claim 12, comprising both amino acid sequences of SEQ ID Nos. 1 and 17.

14. (New) The isolated peptide according to claim 12, wherein the peptide has an N-terminus or C-terminus having a covalently bound immunogenicity enhancing lipid tail.

15. (New) The isolated peptide according to claim 13, wherein the peptide has an N-terminus or C-terminus having a covalently bound immunogenicity enhancing lipid tail.

16. (New) A vaccine for immunization against malaria, said vaccine comprising an effective amount of at least one peptide according to claim 12 together with a pharmaceutically acceptable carrier.

17. (New) A vaccine for immunization against malaria, said vaccine comprising an effective amount of at least one peptide according to claim 13 together with a pharmaceutically acceptable carrier.

18. (New) A method for immunizing against malaria, which method comprises administering to a patient in need thereof an effective amount of an isolated peptide according to claim 12, together with a pharmaceutically acceptable carrier.

IN THE SEQUENCE LISTING

Please replace the paper copy of the Sequence Listing with the attached substitute Sequence Listing.